http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2014108532-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-543 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-54366 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N21-76 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2012-08-21^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-10-10^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2014108532-A |
| titleOfInvention | METHOD FOR PREDICTING A FAVORABLE CLINICAL ANSWER IN THE TREATMENT OF DISORDERS OF NEUROLOGICAL DEVELOPMENT OR NEUROLOGICAL OR NEUROSYCHIATRIC DISEASES |
| abstract | 1. The in vitro method of predicting a response for patients with disorders of the nervous system, neurological or neuropsychiatric disorders, in the treatment of a compound directed to the glutamatergic pathway, comprising the following stages: i) determining the concentration of a protein of one, two, three, four, five or six members of the complement H factor family or a mixture thereof, or a combination thereof in a patient sample, ii) comparing the protein concentration determined in step i) with a representative protein concentration of one o, two, three, four, five or six members of the complement factor H family of patients with disorders of the nervous system, neurological or neuropsychiatric disorders, iii) where a higher protein concentration of one, two, three, four, five or six the members of the complement factor H family in the sample of a patient having disorders of the nervous system, neurological or neuropsychiatric disorders, indicates the patient who will form a favorable clinical response from this cheniya and iv) the choice of treatment for patients with disorders of the nervous system, neurological or neuropsychiatric rasstroystva.2. An in vitro method for predicting a response for patients having a nervous system development disorder, neurological or neuropsychiatric disorder according to claim 1, in the treatment of a glycine reuptake inhibitor (GRI), the method comprising the following steps: i) determining a protein concentration of one, two, three, four, five or six members of the complement H factor family or a mixture thereof, or a combination in |
| priorityDate | 2011-08-26^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 42 of 42.